Genpharmasec Ltd filed a regulatory statement confirming no deviation in use of Rs 48.45 crore Rights Issue proceeds for Q4 FY26.
The company raised funds on 21 February 2024 for acquisition, debt repayment, working capital, and corporate purposes.
Audit Committee reviewed and confirmed full compliance with original objects stated in the Letter of Offer.
All allocated amounts were utilized as planned with zero variation across all four fund utilization categories.